These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 38169820)

  • 1. Oncolytic virotherapy in cancer treatment: challenges and optimization prospects.
    Chen L; Zuo M; Zhou Q; Wang Y
    Front Immunol; 2023; 14():1308890. PubMed ID: 38169820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy with oncolytic viruses: progress and challenges.
    Shalhout SZ; Miller DM; Emerick KS; Kaufman HL
    Nat Rev Clin Oncol; 2023 Mar; 20(3):160-177. PubMed ID: 36631681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatment.
    Wang L; Chard Dunmall LS; Cheng Z; Wang Y
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35640930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses.
    Jafari M; Kadkhodazadeh M; Shapourabadi MB; Goradel NH; Shokrgozar MA; Arashkia A; Abdoli S; Sharifzadeh Z
    Front Immunol; 2022; 13():1012806. PubMed ID: 36311790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The emerging field of oncolytic virus-based cancer immunotherapy.
    Ma R; Li Z; Chiocca EA; Caligiuri MA; Yu J
    Trends Cancer; 2023 Feb; 9(2):122-139. PubMed ID: 36402738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arming oncolytic viruses to leverage antitumor immunity.
    de Gruijl TD; Janssen AB; van Beusechem VW
    Expert Opin Biol Ther; 2015 Jul; 15(7):959-71. PubMed ID: 25959450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic Viruses: Priming Time for Cancer Immunotherapy.
    Russell L; Peng KW; Russell SJ; Diaz RM
    BioDrugs; 2019 Oct; 33(5):485-501. PubMed ID: 31321623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing oncolytic virotherapy in cancer treatment.
    Harrington K; Freeman DJ; Kelly B; Harper J; Soria JC
    Nat Rev Drug Discov; 2019 Sep; 18(9):689-706. PubMed ID: 31292532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic Viruses in Cancer Treatment: A Review.
    Lawler SE; Speranza MC; Cho CF; Chiocca EA
    JAMA Oncol; 2017 Jun; 3(6):841-849. PubMed ID: 27441411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy.
    Chowaniec H; Ślubowska A; Mroczek M; Borowczyk M; Braszka M; Dworacki G; Dobosz P; Wichtowski M
    Front Immunol; 2024; 15():1375433. PubMed ID: 38576614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic Immunotherapy: Can't Start a Fire Without a Spark.
    Muscolini M; Tassone E; Hiscott J
    Cytokine Growth Factor Rev; 2020 Dec; 56():94-101. PubMed ID: 32826166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses.
    Goradel NH; Alizadeh A; Hosseinzadeh S; Taghipour M; Ghesmati Z; Arashkia A; Negahdari B
    Future Oncol; 2022 Jan; 18(2):245-259. PubMed ID: 34821517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic Viruses and Immune Checkpoint Inhibitors: Preclinical Developments to Clinical Trials.
    Hwang JK; Hong J; Yun CO
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33207653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements.
    Yun CO; Hong J; Yoon AR
    Front Immunol; 2022; 13():953410. PubMed ID: 36091031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncolytic Virotherapy: A New Paradigm in Cancer Immunotherapy.
    Volovat SR; Scripcariu DV; Vasilache IA; Stolniceanu CR; Volovat C; Augustin IG; Volovat CC; Ostafe MR; Andreea-Voichița SG; Bejusca-Vieriu T; Lungulescu CV; Sur D; Boboc D
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineering strategies to enhance oncolytic viruses in cancer immunotherapy.
    Tian Y; Xie D; Yang L
    Signal Transduct Target Ther; 2022 Apr; 7(1):117. PubMed ID: 35387984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and application of oncolytic viruses for cancer immunotherapy.
    Ylösmäki E; Cerullo V
    Curr Opin Biotechnol; 2020 Oct; 65():25-36. PubMed ID: 31874424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fueling immune checkpoint blockade with oncolytic viruses: Current paradigms and challenges ahead.
    Li SJ; Sun ZJ
    Cancer Lett; 2022 Dec; 550():215937. PubMed ID: 36206966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OV Modulators of the Paediatric Brain TIME: Current Status, Combination Strategies, Limitations and Future Directions.
    Vazaios K; van Berkum RE; Calkoen FG; van der Lugt J; Hulleman E
    Int J Mol Sci; 2024 May; 25(9):. PubMed ID: 38732225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic viruses combined with immune checkpoint therapy for colorectal cancer is a promising treatment option.
    Ren Y; Miao JM; Wang YY; Fan Z; Kong XB; Yang L; Cheng G
    Front Immunol; 2022; 13():961796. PubMed ID: 35911673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.